Looking at eye tracking’s potential for clinical trials
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
A genome-wide association study lays a foundation for deeper investigation of these variants in neurodevelopmental conditions.
The new tool could help clinicians diagnose autism in children younger than 3, the findings show.
This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.
Brain scans of hundreds of infants suggest that up to 80 percent of those with autism have unusual amounts of cerebrospinal fluid. Researchers are studying how this might contribute to the condition.
The discovery could help clinicians diagnose children who carry mutations in the gene, called SCN2A, and gauge their responses to potential therapies.
In this edition of Null and Noteworthy, researchers upend early interventions and diagnostic boundaries.
By revealing differences between autistic and non-autistic children, it could help identify autism in babies.
Methodological choices and study-site artifacts confounded an attempt to replicate findings in support of an autism brain-imaging biomarker, according to new unpublished work.
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.